Skip to main content

Sarepta hikes full-year sales estimate for Duchenne drug

The FDA approved the drug last year despite limited clinical data and in the face of intense pressure from patient groups. Some insurers are still hesitant to reimburse it.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.